TMEM33

Summary

TMEM33 (transmembrane protein 33, HGNC:25541) is a protein-coding gene on chromosome 4p13, encoding Transmembrane protein 33 (P57088). Acts as a regulator of the tubular endoplasmic reticulum (ER) network by modulating intracellular calcium homeostasis.

Involved in positive regulation of endoplasmic reticulum unfolded protein response; regulation of endoplasmic reticulum tubular network organization; and response to endoplasmic reticulum stress. Located in endoplasmic reticulum membrane; melanosome; and nuclear envelope.

Source: NCBI Gene 55161 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 48 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018126

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25541
Approved symbol	TMEM33
Name	transmembrane protein 33
Location	4p13
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10525, Pom33
Ensembl gene	ENSG00000109133
Ensembl biotype	protein_coding
OMIM	618515
Entrez	55161

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000264452, ENST00000504986, ENST00000506794, ENST00000508448, ENST00000510383, ENST00000513558, ENST00000513702, ENST00000883748, ENST00000883749, ENST00000883750, ENST00000883751, ENST00000927658, ENST00000927659

RefSeq mRNA: 1 — MANE Select: NM_018126 NM_018126

CCDS: CCDS3464

Canonical transcript exons

ENST00000504986 — 7 exons

Exon	Start	End
ENSE00000712704	41939196	41939383
ENSE00002055098	41935429	41935529
ENSE00002083003	41954070	41960803
ENSE00003529454	41949302	41949385
ENSE00003546209	41944793	41944926
ENSE00003554291	41943747	41943814
ENSE00003648204	41938602	41938696

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 95.70.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 67.9983 / max 307.8646, expressed in 1827 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
47500	61.8881	1827
47502	3.6018	1434
47501	1.5171	971
47504	0.4596	199
47503	0.3513	152
203157	0.1804	54

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	95.70	gold quality
buccal mucosa cell	CL:0002336	95.58	gold quality
pigmented layer of retina	UBERON:0001782	94.65	gold quality
retina	UBERON:0000966	94.63	gold quality
islet of Langerhans	UBERON:0000006	93.63	gold quality
mucosa of sigmoid colon	UBERON:0004993	93.53	gold quality
esophagus squamous epithelium	UBERON:0006920	93.44	gold quality
middle temporal gyrus	UBERON:0002771	93.01	gold quality
medial globus pallidus	UBERON:0002477	93.00	gold quality
upper leg skin	UBERON:0004262	92.96	gold quality
colonic mucosa	UBERON:0000317	92.88	gold quality
corpus epididymis	UBERON:0004359	92.71	gold quality
gingiva	UBERON:0001828	92.17	gold quality
gingival epithelium	UBERON:0001949	92.09	gold quality
caput epididymis	UBERON:0004358	92.09	gold quality
globus pallidus	UBERON:0001875	91.95	gold quality
squamous epithelium	UBERON:0006914	91.93	gold quality
mammalian vulva	UBERON:0000997	91.82	gold quality
monocyte	CL:0000576	91.72	gold quality
mononuclear cell	CL:0000842	91.49	gold quality
leukocyte	CL:0000738	91.36	gold quality
duodenum	UBERON:0002114	90.88	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.85	gold quality
blood	UBERON:0000178	90.70	gold quality
tibia	UBERON:0000979	90.69	gold quality
tendon	UBERON:0000043	90.66	gold quality
placenta	UBERON:0001987	90.32	gold quality
corpus callosum	UBERON:0002336	90.26	gold quality
epithelium of esophagus	UBERON:0001976	90.22	gold quality
postcentral gyrus	UBERON:0002581	90.17	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.67
E-MTAB-6524	no	143.40

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

339 targeting TMEM33, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-196A-1-3P	99.99	72.15	2772

Literature-anchored findings (GeneRIF, showing 2)

• TMEM33 is a novel regulator of the PERK-eIE2alpha-ATF4 and IRE1-XBP1 axes of the UPR signaling. (PMID:26268696)
• PKM2-TMEM33 axis regulates lipid homeostasis in cancer cells by controlling SCAP stability. (PMID:34487377)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem33	ENSDARG00000041332
mus_musculus	Tmem33	ENSMUSG00000037720
rattus_norvegicus	Tmem33	ENSRNOG00000002254
drosophila_melanogaster	Kr-h2	FBGN0266449
caenorhabditis_elegans		WBGENE00012555

Protein

Protein identifiers

Transmembrane protein 33 — P57088 (reviewed: P57088)

Alternative names: Protein DB83, SHINC-3

All UniProt accessions (5): P57088, D6RAA6, D6RBY2, H0Y8N0, J3KN43

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a regulator of the tubular endoplasmic reticulum (ER) network by modulating intracellular calcium homeostasis. Mechanistically, stimulates PKD2 calcium-dependent activity. Suppresses the RTN3/4-induced formation of the ER tubules. Positively regulates PERK-mediated and IRE1-mediated unfolded protein response signaling. Plays an essential role in VEGF-mediated release of Ca(2+) from ER stores during angiogenesis. Also plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26. Participates in lipid metabolism by acting as a downstream effector of the pyruvate kinase/PKM. Forms a complex with RNF5 to facilitate polyubiquitination and subsequent degradation of SCAP on the ER membrane.

Subunit / interactions. Interacts with EIF2AK3. Interacts with ARL6IP1, isoform RTN1-A of RTN1, isoform RTN2-B of RTN2, isoform 3 of RTN3 and isoform 3 of RTN4. Interacts with RNF5. Interacts with RNF26. Interacts with PKD2.

Subcellular location. Endoplasmic reticulum membrane. Melanosome. Nucleus envelope.

Tissue specificity. Prostate cancer and several cancer cell lines (at protein level). Widely expressed. Expressed at higher levels in endocrine-resistant breast cancer cells as compared to endocrine-sensitive breast cancer cells. Expressed at higher levels in early recurrence breast cancer tissues as compared to non-recurrent breast tumors.

Induction. By endoplasmic reticulum (ER) stress.

Similarity. Belongs to the PER33/POM33 family.

RefSeq proteins (1): NP_060596* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005344	TMEM33/Pom33	Family
IPR051645	PER33/POM33_regulator	Family

Pfam: PF03661

UniProt features (11 total): topological domain 4, transmembrane region 3, initiator methionine 1, chain 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P57088-F1	88.85	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 234 (showing top): ELVIDGE_HYPOXIA_DN, HORIUCHI_WTAP_TARGETS_DN, GOBP_IRE1_MEDIATED_UNFOLDED_PROTEIN_RESPONSE, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, AACYNNNNTTCCS_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_TOPOLOGICALLY_INCORRECT_PROTEIN, ATGTTAA_MIR302C, GOBP_REGULATION_OF_IRE1_MEDIATED_UNFOLDED_PROTEIN_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_ER_NUCLEUS_SIGNALING_PATHWAY, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GARY_CD5_TARGETS_DN, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION

GO Biological Process (8): response to endoplasmic reticulum stress (GO:0034976), innate immune response (GO:0045087), membrane organization (GO:0061024), endoplasmic reticulum tubular network organization (GO:0071786), regulation of endoplasmic reticulum tubular network organization (GO:1903371), positive regulation of IRE1-mediated unfolded protein response (GO:1903896), positive regulation of PERK-mediated unfolded protein response (GO:1903899), immune system process (GO:0002376)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): nuclear envelope (GO:0005635), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), melanosome (GO:0042470), nucleus (GO:0005634), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of endoplasmic reticulum unfolded protein response	2
endomembrane system	2
intracellular membrane-bounded organelle	2
cellular response to stress	1
immune response	1
defense response to symbiont	1
cellular component organization	1
endoplasmic reticulum organization	1
regulation of organelle organization	1
endoplasmic reticulum tubular network organization	1
IRE1-mediated unfolded protein response	1
regulation of IRE1-mediated unfolded protein response	1
PERK-mediated unfolded protein response	1
regulation of PERK-mediated unfolded protein response	1
biological_process	1
binding	1
nucleus	1
organelle envelope	1
cytoplasm	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
pigment granule	1
cellular anatomical structure	1

Protein interactions and networks

STRING

890 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM33	RTN1	Q16799	802
TMEM33	ENDOD1	O94919	706
TMEM33	RNF26	Q9BY78	677
TMEM33	TMEM43	Q9BTV4	645
TMEM33	NUP210	Q8TEM1	640
TMEM33	REEP5	Q00765	616
TMEM33	SLC30A9	Q6PML9	607
TMEM33	NUP133	Q8WUM0	606
TMEM33	AHCTF1	Q8WYP5	563
TMEM33	SEC13	P55735	558
TMEM33	TMED1	Q13445	529
TMEM33	NUP85	Q9BW27	528
TMEM33	NDC1	Q9BTX1	526
TMEM33	CFAP299	Q6V702	504
TMEM33	PKD2	Q13563	492

IntAct

192 interactions, top by confidence:

A	B	Type	Score
MAP3K14	CHUK	psi-mi:“MI:0914”(association)	0.950
EMC3	EMC8	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
BRAF	KRAS	psi-mi:“MI:0914”(association)	0.680
TMEM33	MTNR1A	psi-mi:“MI:0915”(physical association)	0.660
MAPK7	PFDN6	psi-mi:“MI:0914”(association)	0.640
RAF1	CALU	psi-mi:“MI:0914”(association)	0.640
	DDX3X	psi-mi:“MI:0914”(association)	0.630
TMEM33		psi-mi:“MI:0915”(physical association)	0.560
MTNR1A	PGRMC1	psi-mi:“MI:0914”(association)	0.530
	XPO1	psi-mi:“MI:0914”(association)	0.530
SLC30A2	ESYT2	psi-mi:“MI:0914”(association)	0.530
ERBB2	NDUFA4	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480

BioGRID (275): ABCC1 (Co-fractionation), TMEM33 (Affinity Capture-MS), TMEM33 (Proximity Label-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Reconstituted Complex), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS), TMEM33 (Affinity Capture-MS)

ESM2 similar proteins: A0MT11, A4FV75, A4QNE0, A5A6S6, A6H7C2, A6ZIQ8, O35841, O80845, P56589, P57088, Q10SM7, Q148K5, Q15005, Q28250, Q2KII7, Q2TBU2, Q3TMP8, Q3ZBE6, Q4R512, Q4R5B4, Q5BJI9, Q5M8Y1, Q5R644, Q5RAY6, Q5RF53, Q5U4F4, Q5VRJ8, Q5XIK2, Q5ZKG8, Q60HE1, Q6GLK9, Q6GQ39, Q6NRL4, Q84JW1, Q86UB9, Q91XC9, Q9BZZ5, Q9CR67, Q9CYN2, Q9CYV5

Diamond homologs: P57088, Q9CR67, Q9V447, Q9XWV0, Q9Z142

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 209 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
CD209 (DC-SIGN) signaling	5	17.5×	6e-04
RAF activation	7	15.9×	2e-04
Signaling by high-kinase activity BRAF mutants	7	15.0×	2e-04
MAP2K and MAPK activation	7	13.5×	2e-04
Negative regulation of MAPK pathway	7	12.6×	2e-04
Signaling by moderate kinase activity BRAF mutants	7	12.0×	2e-04
Paradoxical activation of RAF signaling by kinase inactive BRAF	7	12.0×	2e-04
Signaling downstream of RAS mutants	7	12.0×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
regulation of intracellular pH	8	26.6×	6e-07
bicarbonate transport	6	26.6×	5e-05
MAPK cascade	10	8.5×	2e-04
transmembrane transport	9	8.4×	5e-04
response to ethanol	8	6.5×	9e-03
cell migration	12	4.1×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1156 predictions. Top by Δscore:

Variant	Effect	Δscore
4:41935915:A:T	donor_gain	1.0000
4:41935963:G:T	donor_gain	1.0000
4:41938600:A:AG	acceptor_gain	1.0000
4:41938601:G:GG	acceptor_gain	1.0000
4:41939290:T:G	donor_gain	1.0000
4:41939378:TTAC:T	donor_gain	1.0000
4:41943746:GT:G	acceptor_gain	1.0000
4:41943746:GTGA:G	acceptor_gain	1.0000
4:41944789:TTA:T	acceptor_loss	1.0000
4:41944790:TA:T	acceptor_loss	1.0000
4:41944790:TAGG:T	acceptor_gain	1.0000
4:41944791:A:AC	acceptor_loss	1.0000
4:41944791:A:AG	acceptor_gain	1.0000
4:41944792:G:A	acceptor_loss	1.0000
4:41944792:G:GG	acceptor_gain	1.0000
4:41944792:GGC:G	acceptor_gain	1.0000
4:41944792:GGCA:G	acceptor_gain	1.0000
4:41944792:GGCAA:G	acceptor_gain	1.0000
4:41944924:TAGG:T	donor_loss	1.0000
4:41944925:AGGT:A	donor_loss	1.0000
4:41944926:GGTA:G	donor_loss	1.0000
4:41944927:G:GA	donor_loss	1.0000
4:41944927:G:GG	donor_gain	1.0000
4:41944928:T:G	donor_loss	1.0000
4:41949300:A:AG	acceptor_gain	1.0000
4:41949300:AGT:A	acceptor_gain	1.0000
4:41949301:G:GT	acceptor_gain	1.0000
4:41949301:GT:G	acceptor_gain	1.0000
4:41949301:GTG:G	acceptor_gain	1.0000
4:41935450:C:CA	acceptor_gain	0.9900

AlphaMissense

1608 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:41939251:A:C	S66R	1.000
4:41939253:T:A	S66R	1.000
4:41939253:T:G	S66R	1.000
4:41939255:C:A	A67D	1.000
4:41939264:T:C	L70P	1.000
4:41939326:G:C	D91H	1.000
4:41939326:G:T	D91Y	1.000
4:41939327:A:C	D91A	1.000
4:41939327:A:G	D91G	1.000
4:41939327:A:T	D91V	1.000
4:41939342:T:C	L96P	1.000
4:41943770:T:C	F118L	1.000
4:41943772:C:A	F118L	1.000
4:41943772:C:G	F118L	1.000
4:41944878:C:A	A161D	1.000
4:41944887:A:T	E164V	1.000
4:41944890:T:A	I165K	1.000
4:41949342:T:C	F191L	1.000
4:41949343:T:C	F191S	1.000
4:41949344:T:A	F191L	1.000
4:41949344:T:G	F191L	1.000
4:41949346:T:C	L192P	1.000
4:41949364:C:T	S198F	1.000
4:41949374:C:A	N201K	1.000
4:41949374:C:G	N201K	1.000
4:41938638:T:A	W28R	0.999
4:41938638:T:C	W28R	0.999
4:41939218:T:G	Y55D	0.999
4:41939228:C:A	A58D	0.999
4:41939231:T:C	L59S	0.999

dbSNP variants (sampled 300 via entrez): RS1000045598 (4:41956890 A>C), RS1000112069 (4:41949069 A>G), RS1000135817 (4:41944557 G>A), RS1000177840 (4:41935776 A>G), RS1000225819 (4:41942284 A>G), RS1000383839 (4:41951006 A>G), RS1000674583 (4:41959676 A>C), RS1000783324 (4:41952661 G>A), RS1000818318 (4:41951204 A>AAATGTGT), RS1000835254 (4:41954731 G>A), RS1000863963 (4:41936114 G>A), RS1000886183 (4:41954459 A>G), RS1001066590 (4:41947969 A>G), RS1001382082 (4:41955819 G>A,T), RS1001435673 (4:41940801 CCTT>C)

Disease associations

OMIM: gene MIM:618515 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005355_3	Helping behaviour (self reported)	5.000000e-07
GCST005355_5	Helping behaviour (self reported)	3.000000e-06
GCST006940_94	Neurociticism	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724606 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.28	Kd	5.302	nM	CHEMBL5653589
8.28	ED50	5.302	nM	CHEMBL5653589
6.44	IC50	360	nM	MOLIBRESIB
5.31	Kd	4889	nM	CHEMBL3752910
5.31	ED50	4889	nM	CHEMBL3752910

PubChem BioAssay actives

3 with measured affinity, of 10 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149613: Binding affinity to human TMEM33 incubated for 45 mins by Kinobead based pull down assay	kd	0.0053	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178717: Inhibition of TMEM33 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.3600	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149613: Binding affinity to human TMEM33 incubated for 45 mins by Kinobead based pull down assay	kd	4.8887	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Cadmium Chloride	increases abundance, increases expression, decreases expression	3
Valproic Acid	decreases expression, increases expression	2
Cyclosporine	increases expression	2
geldanamycin	increases expression	1
2,4,6-tribromophenol	decreases expression	1
methylmercuric chloride	increases expression, decreases expression	1
triphenyl phosphate	affects expression	1
decabromobiphenyl ether	decreases expression	1
beta-lapachone	increases expression	1
tetrabromobisphenol A	decreases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
chromium hexavalent ion	increases abundance, increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652655	Binding	Binding affinity to human TMEM33 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.